[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-sexual-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-sexual-dysfunction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,71,95,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639464","assessment-of-female-sexual-function-index-fsfi-scores-at-1-month-after-endometrial-sampling-performed-under-sedo-analgesia-or-local-anesthesia-100639464",false,"NCT07628660","Assessment of Female Sexual Function Index (FSFI) Scores at 1 Month After Endometrial Sampling Performed Under Sedo-Analgesia or Local Anesthesia","Evaluation of One-Month Female Sexual Function Index (FSFI) Scores in Women Undergoing Endometrial Sampling Under Sedo-Analgesia Versus Local Anesthesia","FSFI-ENDO","Inclusion Criteria:\n\n* Female patients aged 18 to 60 years\n* Undergoing endometrial sampling at the Department of Obstetrics and Gynecology, Prof. Dr. Cemil Taşcıoğlu City Hospital\n* Undergoing the procedure under sedo-analgesia or local anesthesia as part of routine clinical practice\n* Attendance at the 1-month follow-up visit\n* Ability to complete the Female Sexual Function Index (FSFI) questionnaire\n\nExclusion Criteria:\n\n* Age younger than 18 years or older than 60 years\n* Presence of known chronic systemic disease\n* Incomplete clinical or follow-up data\n* Failure to attend the 1-month follow-up visit\n* Inability or unwillingness to complete the FSFI questionnaire","FEMALE","18 Years","60 Years",{"count":21,"type":22},210,"ESTIMATED","OBSERVATIONAL","Endometrial sampling is a commonly performed gynecological procedure used for the diagnosis of abnormal uterine bleeding and endometrial abnormalities. Different anesthetic techniques may be used during the procedure, including sedo-analgesia and local anesthesia.\n\nThe purpose of this prospective observational study is to evaluate whether the anesthetic technique used during endometrial sampling affects female sexual function one month after the procedure. Female sexual function will be assessed using the validated Female Sexual Function Index (FSFI) questionnaire.\n\nA total of 210 women undergoing endometrial sampling at Prof. Dr. Cemil Taşcıoğlu City Hospital will be enrolled. Participants will be assigned to groups according to the anesthetic technique used during their routine clinical care. FSFI scores obtained at the one-month follow-up visit will be compared between women who underwent the procedure under sedo-analgesia and those who received local anesthesia.\n\nSecondary analyses will include comparison of FSFI scores according to symptom status and histopathological diagnosis.\n\nThe findings of this study may contribute to a better understanding of the impact of anesthetic techniques on postoperative sexual health and quality of life in women undergoing gynecological procedures.",[26,27,28,29],"Female Sexual Dysfunction","Endometrial Sampling","Female Sexual Function Index (FSFI)","Abnormal Uterine Bleeding, Unspecified",[31],"Endometrial Sampling,Female Sexual Function Index,Sedo-Analgesia,Local Anesthesia,Abnormal Uterine Bleeding,Sexual Health","RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":36},"2026-04-15",{"date":40,"type":22},"2027-05-15",{"name":42,"class":43},"Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100587739","at-home-neuromodulation-for-female-sexual-dysfunction-100587739","NCT06932302","At-Home Neuromodulation for Female Sexual Dysfunction","Inclusion Criteria:\n\n* Capable of speaking and understanding English.\n* Able to comprehend the clinical study procedures and provide informed consent.\n* Identified as having female sexual dysfunction with a Female Sexual Function Index (FSFI) score of 26.55 or less and a score of 3 or less on one or more of the FSFI subdomains of lubrication, arousal, and orgasm.\n* Willing and able to adhere to the study protocol\n* Able to attend experimental sessions at Michigan Medicine at both the start and conclusion of the study.\n\nExclusion Criteria:\n\n* Not currently sexually active.\n* Pregnant or planning to get pregnant during the study period.\n* History of a neurological disorder or impairments affecting pelvic organ function, including diagnosed with dorsal genital nerve damage, lower motor dysfunction, or other related conditions.\n* Implanted with a neurostimulator for bladder or bowel function.\n* Have a skin condition that would predispose them to sensitivity to the stimulation electrodes.\n* Female sexual dysfunction limited solely to low desire, without issues in lubrication, arousal, or orgasm.\n* Clinically diagnosed bladder dysfunction, pelvic pain, or other pelvic organ symptoms; or a score of 8 or higher on the American Urological Association Symptom Index (AUASI).\n* Unable or unwilling to adhere to the study protocol\n* Simultaneously participating in another research study that may affect the results of this study.","85 Years",{"count":53,"type":22},24,"INTERVENTIONAL",[56],"NA","This pilot study investigates the regular use of non-invasive dorsal genital nerve stimulation (DGS) for the treatment of female sexual dysfunction (FSD). The researchers aim to determine whether subjects with FSD can correctly follow an at-home treatment regimen and to demonstrate that DGS can improve FSD arousal symptoms in premenopausal and postmenopausal women. Some subjects will use a smart vibrator for comparison to DGS.",[26],[60,61],"dorsal genital nerve stimulation","neuromodulation","2025-12-16",{"date":64,"type":36},"2025-12-23",{"date":66,"type":36},"2025-10-15",{"date":68,"type":22},"2027-11",{"name":70,"class":43},"University of Michigan",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":54,"phases":81,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":44},"100574116","phase-2-female-sexual-dysfunction-assessment-and-managment-of-vaginismus-100574116","NCT06755099","Female Sexual Dysfunction Assessment and Managment of Vaginismus","Experience of Vaginismus in Outpatient Attendants in Assiut University Women's Health Hospital: Prevalence, Impact on Quality of Life and Management","Inclusion Criteria:\n\n* • Age from 18to 40 years.\n\n  * Women diagnosed with primary vaginismus.\n\nVaginismus has been classified by Lamont (12) according to its severity into four degrees or grades:\n\n1. In first degree (also known as grade 1 vaginismus), the patient has spasm of the pelvic floor that can be relieved with reassurance.\n2. In the second degree, the spasm is present throughout the pelvis even with reassurance.\n3. In third degree, the patient elevates her buttocks to avoid being examined.\n4. In fourth degree vaginismus, the most severe form of vaginismus, the patient elevates the buttocks, retreats, and tightly closes her thighs to avoid examination\n\nExclusion Criteria:\n\n* Refusing to participate in the study\n\n  * Women whose husbands have an erectile dysfunction.\n  * women with secondary vaginismus.\n  * Women with psychiatric disorders.\n  * Lacking the appropriate cooperation for treatment and follow-up procedure.\n  * Having any contraindications to receiving botulinum, including allergies to albumin, botulinum toxin, or its injection components.\n  * Previous history of treatment with botulinum or physiotherapy.\n  * Infection at the injection site.\n  * Diseases involving nerves and muscles, such as myasthenia gravis and Lambert-Eaton syndrome, vulvodynia, cutaneous problems at the vulva or perineum, anal fissure, urinary duct or rectum disorders, and coagulation disorders urging them to use anticoagulation drugs","40 Years",{"count":80,"type":22},40,[82,83],"PHASE2","PHASE3","The study aims at :\n\n1. The extent female sexual dysfunction problem in community through questionnaire .\n2. Compare effectiveness of two treatment options for vaginismus .",[26],"NOT_YET_RECRUITING","2024-12-24",{"date":89,"type":36},"2025-01-01",{"date":89,"type":22},{"date":92,"type":22},"2026-11-30",{"name":94,"class":43},"Assiut University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":105,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":44},"100572121","effect-of-intradetrusor-onabotulinumtoxina-injection-versus-conservative-management-on-female-sexual-function-in-patients-with-bladder-pain-syndrome-100572121","NCT06729151","Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome","Inclusion Criteria:\n\n* Female 18 years of age and older\n* For bladder pain syndrome participants: O'Leary Sant score 13 or greater\n* For healthy controls: O'Leary Sant score 12 or less\n* DEERS eligible (care provided by military health care system)\n\nExclusion Criteria:\n\n* Contraindications for bladder Botox\n* Current use of alternative treatment for bladder pain syndrome\n* Neurogenic bladder\n* Other urinary tract disease\n* Pelvic organ prolapse stage 3 or greater\n* Pregnancy or breastfeeding\n* Non-English speakers",true,"99 Years",{"count":104,"type":22},159,"12 Weeks","Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS) is estimated to affect 3.3 to 7.9 million women aged 18 years and older in the United States. The American Urological Association (AUA) defines IC\u002FBPS as \"an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes\". IC\u002FBPS significantly impacts quality of life, with the individual domains of sexual function, anxiety and depression, sleep quality and work productivity being specifically affected. Significant sexual dysfunction in women with IC\u002FBPS has been consistently demonstrated across multiple international studies, with a prevalence ranging from 68% to 91%. In fact, among all patients with lower urinary tract symptoms, patients with a diagnosis of IC\u002FBPS had the highest levels of impaired sexual function, mostly due to dyspareunia. Recommended treatments for IC\u002FBPS include dietary and behavioral modifications, oral medications, bladder instillations, bladder hydrodistension, intradetrusor injection of onabotulinumtoxinA and major surgery. Scant research exists on how treating IC\u002FBPS affects sexual function. We are conducting a prospective cohort study to assess for improvement in sexual function following intravesical onabotulinumtoxinA injection versus conservative management for IC\u002FBPS.\n\nThe study will consist of three groups: intradetrusor onabotulinumtoxinA injection, conservative management and age-matched, healthy controls. All patients aged 18 years and older presenting to the Walter Reed National Military Medical Center (WRNMMC) Urogynecology clinic who are given a diagnosis of IC\u002FBPS and have an O'Leary Sant index questionnaire scoring 13 or greater will be eligible for the study. The primary study outcome is change in the pre- and 12-week post-treatment Female Sexual Function Index (FSFI). The secondary outcomes will include changes in the pre- and post-treatment O'Leary Sant index, Patient Global Impression of Improvement (PGI-I), Patient Global Impression of Severity (PGI-S), Pelvic Organ Prolapse\u002FIncontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR), Visual analog pain scale and 24-hour bladder diary (number of daily voids, number of nightly voids, incontinence episode). Adverse events will be monitored, including urinary tract infection or need for urinary catheterization due to urinary retention within 12 weeks of start of treatment. The age-matched, healthy control group will complete only one set of questionnaires to serve as a baseline comparison to the IC\u002FBPS groups. For between-groups comparisons, a sample size of 49 per group will have 80% power to detect a clinically important difference of 4 points if the standard deviation is 7 points, assuming a 5% two-sided significance level. We will therefore recruit 55 subjects per group to allow for approximately 10% attrition between the pre- and post-treatment assessments. This study will be powered to detect a difference between treatments groups, which has not yet been reported in the literature.",[108,26],"Bladder Pain Syndrome","2024-12-06",{"date":111,"type":36},"2024-12-11",{"date":113,"type":36},"2024-11-01",{"date":115,"type":22},"2026-12-31",{"name":117,"class":118},"Walter Reed National Military Medical Center","FED",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":19,"enrollmentInfo":127,"targetDuration":4,"studyType":54,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":44},"100525000","phase-2-evaluation-of-the-efficacy-safety-and-tolerability-of-bz371a-in-women-with-sexual-arousal-disorder-100525000","NCT06116045","Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder","Phase 2 Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women with Sexual Arousal Disorder","Inclusion Criteria:\n\n* Women between the ages 21 and 60;\n* Pre-menopausal or post-menopausal women may be included;\n* May or may not be taking female sex hormones (estrogen with or without progesterone, or their derivatives);\n* FSAD, defined as the inability, persistent or recurrent, to obtain or maintain until the conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris);\n* Women with FSAD who present marked suffering or interpersonal difficulties;\n* Stable relationship for more than 6 months, with a sexually active partner;\n* Ability to read and understand the Informed Consent Form (ICF) and to answer the questionnaires.\n\nExclusion Criteria:\n\n* Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study;\n* Women who do not agree to attempt sexual activity at least twice a week while taking the study medication;\n* History of unresolved sexual trauma or abuse;\n* Diagnosis of vaginismus, genitopelvic pain\u002Fpenetration disorder and\u002For sexual aversion disorder;\n* Uncontrolled diabetes at screening visit (HbA1C \\> 10%);\n* Prior spinal cord injury, with lower limb paralysis;\n* History of abdominal or pelvic surgery that may have damaged pelvic nerves, including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension.\n* Current testosterone use, or long-term testosterone use (such as chip) within the past 6 months;\n* Presence of menstrual irregularity or endocrinopathies that significantly alter the menstrual cycle, preventing Cytocam analyses from taking place at the same time;\n* Patients with current depression, characterized by the use or need for use of psychotropic drugs, including bupropion, lithium, or neuroleptics;\n* Presence of genital lesions that impair analysis of local adverse effects on the genitalia;\n* Presence of diseases that cause excessive vaginal discharge, such as recurrent urinary tract infection, vaginal infection and pelvic inflammatory disease.\n* Abnormal Papanicolaou test within the past 3 years;\n* History of gynecological cancer (history of uterine dysplasia can be included, provided it has been properly treated for at least 6 months);\n* History of pelvic irradiation;\n* Use of topical medications in the genital region that may interfere with PSI assessment as well as their absorption or drug interaction, including vaginal estrogens, lubricants, spermicides, creams or gels, vaginal douches;\n* History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart disease (including history of angina and\u002For heart failure) and nephropathies;\n* Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and sosorbitol dinitrate (Isocord®)\n* ECG findings that are clinically symptomatic, or that, in the Investigator's judgment, are considered significant and pose a risk to the research volunteer's participation;\n* Findings on laboratory tests that, in the Investigator's judgment, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses;\n* TSH outside normal limits for age (participants with hypothyroidism on stable dose of medication, over 3 months, may be included);\n* BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except for situations such as \"white coat\" syndrome\n* Severe hypertension, considered as use of three or more antihypertensives;\n* Diseases that can cause clitoral priapism, such as sickle cell anemia, multiple myeloma or leukemia;\n* History of clitoral priapism;\n* Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in the stool;\n* Pregnant or lactating;\n* Current use of nitric oxide donors, guanylate cyclase stimulators (e.g. Riociguat), or 5- phosphodiesterase inhibitors (Sildenafil, Tadalafil, etc.);\n* Any disease or condition or physical finding that the Investigator considers significant and that increases the risk of the research participant's participation or may interfere with the results, including serious debilitating diseases, presence of cancer, serious mental illness, persistent abuse of medication.","21 Years",{"count":128,"type":22},30,[82],"To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.",[132,26],"Female Sexual Arousal Disorder",[134,135,136,137,138,139],"Female","Sexual arousal disorder","Sexual dysfunction","FSFI questionnaire","Nitric Oxide","Topic","2024-10-18",{"date":142,"type":36},"2024-10-22",{"date":144,"type":36},"2024-10-01",{"date":146,"type":22},"2025-03-31",{"name":148,"class":149},"Biozeus Biopharmaceutical S.A.","INDUSTRY"]